KOSDAQIT & Software133750

MegaMD

₩1,503▲ 0.27%2026-11-18 close
Market Cap
₩35.2B
Turnover
₩46,407,881
Volume
30K
Shares out.
23.4M
PER
7.8×
PBR
0.5×
EPS
₩191
Dividend Yield
4.02%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩60 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit back in the black, revenue still shrinking

MegaMD recorded annual operating profit in 2024 and 2025, but revenue fell from KRW 64.5 billion in 2022 to KRW 34.6 billion in 2025, and third-quarter 2026 revenue and operating profit were both below the prior-year quarter.

  1. 1

    Annual operating profit was KRW 2.24 billion in 2024 and KRW 1.81 billion in 2025, but the 2025 figure fell 18.9% from the prior year.

  2. 2

    Operating profit rebounded from KRW 150 million in the first quarter of 2026 to KRW 995 million in the second and KRW 1.05 billion in the third, yet the third-quarter figure was 37.2% lower than a year earlier.

  3. 3

    Controlling shareholders' net profit for the last four quarters (Q4 2025 to Q3 2026) totaled KRW 4.22 billion, and third-quarter 2026 controlling shareholders' net profit fell 37.9% year on year.

  4. 4

    The debt ratio fell from 42.3% in 2022 to 25.4% in 2025, with total equity of KRW 66.4 billion and total liabilities of KRW 16.9 billion at the end of 2025.

  5. 5

    The value-up plan disclosed in March 2026 set maintaining an operating profit structure in the black and sustainable dividends as its goals.

02

Business structure

MegaMD was founded in 2004 and listed on KOSDAQ in 2015. It runs two business segments: professional exam preparation and certification and lifelong education.

The professional exam segment sells lecture services under brands such as MegaMD, Mega Law School, Mega Lawyers and Mega Patent Attorney, while the certification segment operates remote and lifelong education institutes.

In the first half of 2025, professional exam products and services accounted for roughly 75% of sales and certification for roughly 25%. The same mix held in the third quarter of 2024, when the professional exam segment generated KRW 21.2 billion (72.34%).

Lectures are the largest revenue source: a third-party aggregator puts lecture revenue at about 85% of sales in the second quarter of 2026, with book sales at about 9%.

Core customers are university students and adult candidates preparing for professional licenses and certifications, and demand depends on exam system changes and recruitment numbers. The company also runs offline campuses, including a PEET prep school in Gwangju.

In 2025 it went through a small merger absorbing its subsidiary MegaLand, and it has said no further restructuring is planned after the merger. The 2025 annual report lists one inside director as the representative director of the largest shareholder, so the relationship with that shareholder's group is worth tracking.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.3B₩1.7B17.9%
2025Q4₩7.1B-₩600M−8.0%
2026Q1₩7.8B₩100M1.9%
2026Q2₩9B₩1B11.0%
2026Q3₩8.7B₩1B12.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩64.5B₩2B₩2.1B3.1%3.2%42.3%
2023₩36B-₩3.9B-₩3.2B−10.9%−5.1%36.1%
2024₩36.5B₩2.2B₩3.8B6.1%5.8%32.9%
2025₩34.6B₩1.8B₩2.8B5.2%4.2%25.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue fell from KRW 64.5 billion in 2022 to KRW 36 billion in 2023, a 44.1% decline, then rose to KRW 36.5 billion in 2024 (up 1.2%) and fell to KRW 34.6 billion in 2025 (down 5.2%). 2022 was the largest year and 2025 the smallest in the 2022 to 2025 range.

The company attributed the weak 2023 to the end of the PEET pharmacist exam. Operating profit went from KRW 2 billion in 2022 to an operating loss of KRW 3.94 billion in 2023, then back to an operating profit of KRW 2.24 billion in 2024 and KRW 1.81 billion in 2025 (down 18.9%).

Operating margin was 3.1% in 2022, -10.9% in 2023, 6.1% in 2024 and 5.2% in 2025. The company linked the 2024 return to profit to cost reductions from a restructured business.

Controlling shareholders' net profit went from a net loss of KRW 3.2 billion in 2023 to KRW 3.78 billion in 2024 and KRW 2.79 billion in 2025 (down 26.3%). Net profit including non-controlling interests is disclosed at the same yearly amounts.

By quarter, the third quarter of 2025 posted revenue of KRW 9.32 billion and operating profit of KRW 1.67 billion; the fourth quarter swung to revenue of KRW 7.13 billion (down 23.5% from the prior quarter) and an operating loss of KRW 570 million.

The first quarter of 2026 returned to operating profit of KRW 150 million on revenue of KRW 7.78 billion. Second-quarter revenue reached KRW 9.01 billion (up 15.8% quarter on quarter) with operating profit of KRW 995 million.

Third-quarter revenue of KRW 8.75 billion was down 2.9% quarter on quarter and down 6.2% year on year, while operating profit of KRW 1.05 billion was up 5.3% quarter on quarter but down 37.2% year on year.

Controlling shareholders' net profit peaked at KRW 1.89 billion in the first quarter of 2026 and then fell to KRW 1.59 billion and KRW 1.35 billion. Operating cash flow stayed positive from 2023 to 2025, at KRW 1.05 billion, KRW 8.39 billion and KRW 5.1 billion.

The reason for the fourth-quarter 2025 loss cannot be pinned down from the disclosed figures alone, so the notes in the next annual report are the place to check it.

05

Industry analysis

MegaMD's end market is professional licensing exams and lifelong education, where exam system changes and candidate numbers drive demand. Changes in the examination system, recruitment numbers and lecture content competitiveness have been cited as factors affecting results.

The 2023 slump after the PEET exam ended shows how a single exam's change can swing total sales. Industry commentary cites rising demand for online education, but company revenue fell over the same period. Demand growth in the sector and the company's own sales trend did not move together.

Quarterly revenue in 2026 has ranged between KRW 7.78 billion and KRW 9.01 billion after the 2022 peak. Competition comes from online lecture providers and offline academies in the same exam market.

Direct comparison with listed IT and software peers is limited by very different business mixes, so the difference is better read as a difference in business structure.

Industry exposure therefore rests on exam system and candidate numbers, and the next annual report's revenue trend will show how those variables play out.

06

Outlook

In a value-up plan disclosed on March 27, 2026, the company said it will pursue maintaining an operating profit structure based on expanding market leadership. The same plan presented sustainable dividends as part of shareholder returns and value enhancement. The company stated that its 2025 payout ratio was 47.48%.

It also said it qualifies as a high-dividend company under the Restriction of Special Taxation Act. A cash dividend decision was disclosed on March 12, 2026, with the total amount calculated on shares outstanding excluding treasury shares.

The annual general meeting was held on March 27, 2026, approving director re-elections and articles changes. The board after the meeting has five directors, two of them outside directors, a 40% outside director ratio.

No quantified guidance, new contract wins, capacity expansion or new product timelines were found in the disclosures reviewed. The next checkpoints are whether the operating profit structure holds and whether dividend sustainability is maintained.

Operating profit recovered in recent quarters while controlling shareholders' net profit declined, so whether these two lines move in the same direction is worth watching.

07

Valuation

PER
7.8×
PBR
0.5×
ROE
6.1%
EPS
₩191
BPS
₩3,156
Dividend per share
₩60

The valuation discussion is framed as relationships rather than point figures. The price-to-book ratio sits below 1x, so the share price is low relative to book equity on the balance sheet.

At the end of 2025, total equity of KRW 66.4 billion was entirely attributable to controlling shareholders, so book-value-based comparisons depend more on the size of equity. Earnings-based multiples are sensitive to profit size.

Controlling shareholders' net profit for the last four quarters totaled KRW 4.22 billion, a small base where a few quarters of decline can move the multiple sharply. Third-quarter 2026 controlling shareholders' net profit fell from a year earlier, so earnings trend matters when reading any multiple.

The 2025 payout ratio of 47.48% means a large share of earnings went to dividends, and a shrinking earnings base can push the payout ratio higher. Historical valuation bands and peer averages change with the reference period.

Lower debt relative to assets supports the balance sheet, while small earnings make earnings-based multiples volatile.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Operating profit structure and quarterly recovery

Operating profit rose from KRW 150 million in the first quarter of 2026 to KRW 995 million in the second and KRW 1.05 billion in the third. Two consecutive quarters of increases from the second quarter through the third quarter show quarterly profitability improving. The company has named maintaining an operating profit structure in the black as a goal.

Balance sheet improvement and cash flow

The debt ratio fell from 42.3% in 2022 to 25.4% in 2025, and total equity of KRW 66.4 billion far exceeds total liabilities of KRW 16.9 billion. Operating cash flow was positive in both 2024 and 2025, at KRW 8.39 billion and KRW 5.1 billion. Operating cash flow turned positive from KRW -8.26 billion in 2022, which supports financial capacity.

Shareholder return policy spelled out

The company stated a 2025 payout ratio of 47.48% and said it qualifies as a high-dividend company under the Restriction of Special Taxation Act. It explained the total dividend was calculated on shares outstanding excluding treasury shares.

With the dividend policy set out in disclosures, dividend sustainability can be checked against the size of earnings.

09

Bear factors

Continued revenue contraction

Revenue fell from KRW 64.5 billion in 2022 to KRW 36 billion in 2023, a 44.1% drop, and to KRW 34.6 billion in 2025. Third-quarter 2026 revenue of KRW 8.75 billion was down 6.2% year on year. Press reports said second-quarter 2026 revenue also fell 8.2% from a year earlier.

Earnings volatility and loss periods

Loss periods have recurred, including the KRW 3.94 billion operating loss in 2023 and the KRW 570 million operating loss in the fourth quarter of 2025. Third-quarter 2026 operating profit fell 37.2% year on year, and controlling shareholders' net profit fell 37.9%. The company has said the weak 2023 mainly reflected the end of the PEET pharmacist exam.

Slowing earnings trend

Controlling shareholders' net profit totaled KRW 4.22 billion over the last four quarters and has declined since peaking at KRW 1.89 billion in the first quarter of 2026, to KRW 1.59 billion and KRW 1.35 billion. Full-year 2025 controlling shareholders' net profit fell 26.3% to KRW 2.79 billion. With earnings this small, a continued decline would weigh directly on earnings-based indicators.

10

Risk factors

Exam system and demand risk

The company attributed weak 2023 results to the end of the PEET pharmacist exam. Professional exam revenue depends on exam system changes and recruitment numbers. The timing and scale of demand shifts from system changes are hard to predict from disclosures alone.

Earnings volatility

Operating margin moved from -10.9% in 2023 to 6.1% in 2024 and 5.2% in 2025. Quarterly profit is thin, with a fourth-quarter 2025 operating loss and first-quarter 2026 operating profit of KRW 150 million, so small changes in costs or revenue can shift quarterly results sharply.

Governance and related-party risk

The 2025 half-year report lists one inside director as the representative director of the largest shareholder. The company said no further restructuring is planned after the subsidiary merger, but dealings with affiliated companies and decision-making structure remain items to follow in periodic reports.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    Check whether 2026 annual revenue moved from KRW 34.6 billion in 2025 and whether operating margin holds near 5.2%. Also compare fourth-quarter 2026 results with the fourth-quarter 2025 operating loss.

  2. Around March 2027 (year-end dividend decision and general meeting)

    Check the scale and payout ratio of the fiscal 2026 year-end dividend, and how it is set while earnings are declining. Also check whether progress on the value-up plan is disclosed alongside the shareholder meeting materials.

  3. Mid-May 2027 (first-quarter report filing deadline)

    Check whether first-quarter 2027 operating profit stays in the black compared with KRW 150 million in the first quarter of 2026. Also check whether controlling shareholders' net profit fell further from KRW 1.35 billion in the third quarter of 2026.

  4. Around August 2027 (second-quarter results release)

    Check whether operating profit continues the path from KRW 995 million in the second quarter of 2026 and KRW 1.05 billion in the third. Also check whether the four-quarter controlling shareholders' net profit total of KRW 4.22 billion holds its trend.

12

Overall view

MegaMD's disclosed results swung from an operating loss in 2023 back to operating profit in 2024 and 2025, but revenue fell from KRW 64.5 billion in 2022 to KRW 34.6 billion in 2025.

Quarterly results in 2026 recovered from a first-quarter operating profit of KRW 150 million, yet third-quarter operating profit and revenue were both below the prior-year quarter.

The balance sheet looks relatively stable, with the debt ratio down from 42.3% in 2022 to 25.4% in 2025 and total equity well above total liabilities. On shareholder returns, the company disclosed a 2025 payout ratio of 47.48% and high-dividend company status.

Revenue volatility tied to exam systems and recruitment numbers, and sensitivity of quarterly results to a small earnings base, remain. On valuation, the price-to-book ratio sits below 1x, and earnings-based multiples are affected by the recent decline in profit.

The next checkpoints are 2026 annual revenue and operating margin in the annual report, the fiscal 2026 dividend decision, and whether operating profit stays in the black in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. digitaltoday.co.kr
  2. comp.fnguide.com
  3. job-post.co.kr
  4. kind.krx.co.kr
  5. butler.works
  6. marketbz.com
  7. digitaltoday.co.kr
  8. thinkpool.com
  9. kind.krx.co.kr
  10. saramin.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. news.nate.com
  15. edaily.co.kr
  16. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis